{
    "clinical_study": {
        "@rank": "109521", 
        "brief_summary": {
            "textblock": "RATIONALE: Diagnostic procedures, such as PET and MRI scans, may help to measure a patient's\n      response to treatment.\n\n      PURPOSE: This diagnostic trial is studying how well PET and/or MRI scans work in assessing\n      changes in tumor blood supply in patients receiving antiangiogenesis therapy."
        }, 
        "brief_title": "PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy", 
        "condition": "Unspecified Adult Solid Tumor, Protocol Specific", 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Evaluate the ability of positron emission tomography (PET) to assess the effect of\n           therapy directed against tumor vasculatures on tumor blood flow and tumor blood volume\n           in patients enrolled on a treatment protocol evaluating a therapeutic modality\n           effecting the tumor associated vasculature.\n\n        -  Evaluate the ability of PET to assess the effects of this type of therapy regimen on\n           tumor uptake of fluorodeoxyglucose in these patients.\n\n        -  Evaluate the ability of magnetic resonance imaging (MRI) to assess the effects of\n           therapy directed against the tumor vasculature on tumor blood flow and tumor vascular\n           density in these patients.\n\n        -  Compare the findings on PET and/or MRI with those obtained from conventional CT in this\n           patient population.\n\n      OUTLINE: This is a diagnostic study conducted concurrently with a therapeutic modality\n      study.\n\n      Patients have magnetic resonance imaging and/or positron emission tomography (PET) scans\n      performed prior to start of therapy, 6 weeks and 16 weeks following the initiation of\n      therapy, and 6 weeks following the completion of therapy. Each scan requires about 1-3\n      hours. Patients receive up to 3 different PET scans including tumor blood flow scan with\n      H2015, tumor blood volume scan with 11CO, and glucose uptake scan with fludeoxyglucose F 18.\n\n      PROJECTED ACCRUAL: A total of 145 patients will be accrued for this study within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Eligible for a treatment protocol evaluating a therapeutic modality that may have an\n             effect on tumor associated vasculature\n\n          -  Measurable or evaluable disease by standard CT or MRI\n\n          -  At least 1 lesion measuring greater than 2 cm in diameter\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Over 18\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  No pacemakers, aneurysm clips, shrapnel injury, or implantable electronic devices\n\n          -  Weight no greater than 136 kilograms\n\n          -  No sensitivity to contrast agents that cannot be controlled with premedication\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy\n\n          -  Not specified\n\n        Chemotherapy\n\n          -  Not specified\n\n        Endocrine therapy\n\n          -  Not specified\n\n        Radiotherapy\n\n          -  Not specified\n\n        Surgery\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "145", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2001", 
        "id_info": {
            "nct_alias": "NCT00001709", 
            "nct_id": "NCT00019565", 
            "org_study_id": "980163", 
            "secondary_id": [
                "98-C-0163", 
                "CDR0000066720"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "magnetic resonance imaging", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "fludeoxyglucose F 18", 
                "intervention_type": "Radiation"
            }
        ], 
        "keyword": "unspecified adult solid tumor, protocol specific", 
        "lastchanged_date": "April 23, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/NCI-98-C-0163"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892-1182"
                }, 
                "name": "Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature", 
        "overall_official": {
            "affiliation": "NCI - Surgery Branch", 
            "last_name": "Steven K. Libutti, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2008", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00019565"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "National Institutes of Health Clinical Center (CC)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 1998", 
        "study_design": "Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "September 2007"
    }, 
    "geocoordinates": {
        "Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office": "38.985 -77.095"
    }
}